Navigation Links
Aequus BioPharma Appoints Ronald J. Berenson, M.D. President and CEO
Date:12/10/2012

SEATTLE, Dec. 10, 2012 /PRNewswire/ -- Aequus BioPharma, a majority owned subsidiary of Cell Therapeutics, Inc., announced today that Ronald J. Berenson, M.D. was appointed President and CEO of Aequus. In his new position, Dr. Berenson will expand business and product development opportunities for Aequus' GlycoPolymer technology. Aequus is currently developing its GlycoPolymer technology aimed at creating novel biopharmaceuticals with improved pharmacokinetic properties that require less frequent injections than current therapies.

Dr. Berenson has more than 20 years of senior management experience in biotechnology, and was most recently an Entrepreneur in Residence at the University of Washington. He previously co-founded and served as President and CEO of HemaQuest Pharmaceuticals during the company's first three years, successfully ushering the company's programs into early clinical development of its lead compounds. His background also includes senior executive roles at numerous oncology-focused biotechnology companies, including Founder, Director, President and CEO of Xcyte Therapies, Inc. (which merged with Cyclacel), and Founder, Director, Executive Vice President, Chief Medical Officer and Chief Scientific Officer for CellPro, Inc. (CellPro). At CellPro, he was responsible for regulatory submissions that resulted in the U.S. Food and Drug Administration's (FDA) approval of CellPro's lead product, which was the first FDA-approved biological product in cell therapy. Since 2001, he has been on the Board of Ambassadors of the Fred Hutchinson Cancer Center. Dr. Berenson also has contributed to over 90 publications and holds 10 US patents. He completed his oncology training at Stanford University Medical Center, M.D. from Yale Medical School and obtained his B.S. from Stanford University.

"There are more than 100 therapeutic proteins on the market, and they represent one of the fastest growing classes of drugs today. Patient convenience and co
'/>"/>

SOURCE Aequus BioPharma, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cell Therapeutics Aequus BioPharma Validates its Proprietary GlycoPolymer Technology for the Extension of the Half-life of Therapeutic Protein Drugs
2. Biopharma M&A Trends Hold Steady, But Deals Declined in 2011
3. Enox Biopharma, Inc. To Present Today At IN3 Medical Device 360 Conference In London
4. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
5. Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2012 Financial Results
6. Genesis Biopharma Announces Termination of Previously Announced Proposed Public Offering
7. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2012 Financial Results
8. S1 Biopharma Expands Focus to Include Male Sexual Health
9. New Study Details Foreign Efforts To Lure Biopharmaceutical Companies
10. Keryx Biopharmaceuticals Announces Upcoming Poster Presentation of Zerenex™ (ferric citrate) at the 49th ERA-EDTA Congress
11. Galena Biopharma, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... Lilly and Company (NYSE: LLY ) and AstraZeneca ... entered into a clinical trial collaboration to evaluate the ... checkpoint inhibitor, MEDI4736, in combination with CYRAMZA ® ... planned study will assess the combination as a treatment ... Phase I study is expected to establish the safety ...
(Date:5/28/2015)... INDIANAPOLIS , May 28, 2015  Eli Lilly and ... of its previously announced cash tender offer for up to ... debt securities. Holders of notes who tendered, and ... p.m., New York City time, on ... accepted for purchase by Lilly, are eligible to receive the ...
(Date:5/28/2015)... , May 28, 2015 ... announced the addition of Jain PharmaBiotech,s new ...  to their offering.       ... or gene silencing involves the use of ... cell, this material is processed into short ...
Breaking Medicine Technology:Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 2Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 3Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 4Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 5Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 6Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 7Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 8Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 9Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 10Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 11Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 12Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 13Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 14Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 2Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 3Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 4Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 5Global RNAi Market Report 2015-2024 - Technologies, Markets and Companies 2Global RNAi Market Report 2015-2024 - Technologies, Markets and Companies 3
... Dec. 16, 2010 Solta Medical, Inc. (Nasdaq: ... tightening and a market leader in aesthetic skin treatments, today ... revolutionary Thermage and Fraxel devices that have helped to build ... device industry. The milestone reflects how much the ...
... 2010 Poniard Pharmaceuticals, Inc. (Nasdaq: PARD ... today announced that it has provided notice of voluntary ... Business Financial Services Inc. and Silicon Valley Bank.  The ... on the facility, including interest and other fees payable ...
Cached Medicine Technology:Solta Medical Ships One Millionth Tip for Thermage and Fraxel Devices 2Solta Medical Ships One Millionth Tip for Thermage and Fraxel Devices 3Poniard Pharmaceuticals Announces Plan for Voluntary Prepayment of Term Loan and Transfer to Nasdaq Capital Market 2Poniard Pharmaceuticals Announces Plan for Voluntary Prepayment of Term Loan and Transfer to Nasdaq Capital Market 3Poniard Pharmaceuticals Announces Plan for Voluntary Prepayment of Term Loan and Transfer to Nasdaq Capital Market 4
(Date:5/30/2015)... May 30, 2015 Twelve of the ... by their peers as the 2015 Giants of ... at the Chicago Illuminating Company last night. The awardees ... oncologists for landmark achievements in translational research, gene therapy, ... course of cancer treatment. , Honorees were introduced and ...
(Date:5/30/2015)... You've probably heard that using cotton swabs to clean the ... found a better way to remove ear wax? Luckily, a ... need. , They developed SUNDENG EAR CLEANER to ease the ... from the ears. What's more, it is safer and more ... today for children and adults of all ages. As such, ...
(Date:5/30/2015)... 30, 2015 Thousands of aesthetic industry ... Meeting, sponsored by the American Society for Aesthetic Plastic ... hand was Zeltiq, the parent company of one of ... With blazing growth, the one-of-a-kind device just sold ... Zeltiq is currently in the news for gaining the ...
(Date:5/30/2015)... The results of a 40+ year study in ... to cause mesothelioma, regardless of the volume of exposure. ... Surviving Mesothelioma website. , The study conducted by ... found that, among the 138 cases of mesothelioma that ... of them happened at plants that had, at some ...
(Date:5/30/2015)... May 30, 2015 On Thursday, ... Dr. Charles Simone and Dr. Evan Alley both ... ‘Meet the Mesothelioma Experts’ series. The interview was ... mesothelioma centers of excellence. Drs. Simone and Alley ... Mary Hesdorffer, with whom they discussed the mesothelioma ...
Breaking Medicine News(10 mins):Health News:OncLive’s 2015 Giant of Cancer Care™ Awards Announced 2Health News:OncLive’s 2015 Giant of Cancer Care™ Awards Announced 3Health News:OncLive’s 2015 Giant of Cancer Care™ Awards Announced 4Health News:Improved Ear Hygiene Tool Invented by InventHelp Clients (KSC-952) 2Health News:Dr. Paul Vitenas Meets with Zeltiq President and CEO in Montreal 2Health News:Dr. Paul Vitenas Meets with Zeltiq President and CEO in Montreal 3Health News:New Study Finds Close Link Between Crocidolite Asbestos and Deadly Mesothelioma, According to Surviving Mesothelioma 2Health News:Interview with Mesothelioma Experts, Drs. Simone and Alley Now Available on Demand 2
... unlikely to be caused by a decrease in mammography screening, ... Journal of the National Cancer Institute . It is ... , There has been a recent, rapid decline in ... Initiative study found that hormone therapy was associated with an ...
... B: apo A-I ratio is not a better predictor ... that include total cholesterol and HDL-C, according to a ... Current risk-prediction instruments and guidelines for coronary heart disease ... (LDL-C), total cholesterol, or both for CHD risk assessment. ...
... can diagnose venous thromboembolic disease (VTED) in cancer patients ... the thorax, abdomen, and pelvis which are regularly done ... according to a recent study conducted by radiologists at ... , Venous thromboembolic disease can be fatal if left ...
... warfarin) and antiplatelet drugs (e.g., acetylsalicylic acid) are ... diseases. In this study, Joseph Delaney MSc, Dr. ... in 4,028 cases with a diagnosis of gastrointestinal ... Kingdom. They documented a 46-fold increase in the ...
... Spirometry testing is a widely accepted and encouraged ... new research shows that it is not used nearly ... CHEST, the peer-reviewed journal of the American College of ... patients with a COPD diagnosis ever received spirometry testing. ...
... in a nursing home or take medication to lower ... following hospitalization for heatstroke, according to a study posted ... issue of Archives of Internal Medicine, one of the ... online today found that being confined to bed, not ...
Cached Medicine News:Health News:Drop in breast cancer incidence linked to hormone use, not mammograms 2Health News:Use of certain lipid measures not more effective in predicting coronary heart disease 2Health News:Study says COPD testing is not measuring up 2Health News:Study, meta-analysis examine factors associated with death from heatstroke 2Health News:Study, meta-analysis examine factors associated with death from heatstroke 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: